STOCK TITAN

Ocugen, Inc. - $OCGN STOCK NEWS

Welcome to our dedicated page for Ocugen news (Ticker: $OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ocugen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ocugen's position in the market.

Rhea-AI Summary
Ocugen, Inc. announced that Dr. Shankar Musunuri will participate in a fireside chat at the Emerging Growth Virtual Healthcare Equity Conference. The chat will focus on the Company's recent business and clinical development progress, including FDA clearance for a Phase 3 clinical trial for OCU400, a gene therapy for retinitis pigmentosa.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
conferences
-
Rhea-AI Summary
Ocugen, Inc. announces positive EMA opinion on OCU400 Phase 3 clinical trial for retinitis pigmentosa, aligning with FDA clearance. EMA's review supports the trial's design and statistical analysis, paving the way for Marketing Authorization Application submission. OCU400, a gene therapy, targets RP patients with RHO gene mutations and gene agnostic mutations. The positive opinion from EMA streamlines the approval process, potentially reducing time and costs for EU marketing authorization, with OCU400 on track for BLA and MAA approvals by 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
none
-
Rhea-AI Summary
Ocugen, Inc. announces FDA clearance for Phase 3 clinical trial of OCU400 gene therapy for retinitis pigmentosa, a significant milestone in the treatment of RP patients. The trial includes 150 participants with a gene-agnostic approach and aims to address unmet medical needs in RP treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
Rhea-AI Summary
Ocugen, Inc. receives DSMB approval to proceed with medium dose cohort dosing in the Phase 1/2 ArMaDa clinical trial for OCU410, establishing low dose as safe and tolerable. No serious adverse events reported, marking a significant milestone in the clinical development of OCU410.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.19%
Tags
-
Rhea-AI Summary
Ocugen, Inc. announces alignment with FDA for broad retinitis pigmentosa indication in Phase 3 clinical trial of OCU400 gene therapy program. The company also received RMAT designation for OCU400. Ocugen provided a general business update for 2023 and highlighted progress on modifier gene therapy programs for blindness diseases. The Phase 1/2 study results for RP patients were recognized by the FDA. OCU410 and OCU410ST gene therapy programs for GA and Stargardt disease are enrolling patients. Ocugen's mucosal vaccine candidate, OCU500, was chosen for NIAID Project NextGen initiative. The Company's regenerative cell therapy platform, NeoCart, is on track for a Phase 3 trial. Financially, Ocugen plans to restate its financial statements for 2022 and 2023 but expects no impact on cash position or projections. Cash, cash equivalents, and investments totaled $39.5 million as of December 31, 2023. The company had 256.6 million shares of common stock outstanding as of that date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.39%
Tags
none
-
Rhea-AI Summary
Ocugen, Inc. announces that the Data Safety and Monitoring Board (DSMB) has approved proceeding with the medium dose of OCU410ST in the OCU410ST clinical trial for Stargardt disease. The favorable safety and tolerability profile of OCU410ST allows for evaluation of higher doses, addressing the unmet medical need for Stargardt patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.39%
Tags
none
Rhea-AI Summary
Ocugen, a biotechnology company, will host a conference call to provide a business update with financials for 2023. The call will take place on April 2, 2024, at 8:30 a.m. ET. Dial-in numbers and webcast details are provided for participation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.39%
Tags
conferences
-
Rhea-AI Summary
Ocugen, Inc. appoints Dr. Huma Qamar as Chief Medical Officer (CMO) to lead clinical development. Dr. Qamar's rich background in clinical research and expertise in various therapeutic areas positions Ocugen well for future success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.63%
Tags
management
-
Rhea-AI Summary
Ocugen completes dosing in the first cohort of Phase 1/2 ArMaDa clinical trial for OCU410, a gene therapy candidate for geographic atrophy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.69%
Tags
Rhea-AI Summary
Ocugen, a biotechnology company, announced that Dr. Shankar Musunuri will be a panelist at the Investing in Cures Summit 2024 to discuss therapeutic approaches for retinal diseases. The event will focus on gene agnostic strategies to address retinal disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
conferences
Ocugen, Inc.

Nasdaq:OCGN

OCGN Rankings

OCGN Stock Data

491.50M
252.38M
1.45%
10.33%
16.95%
Sanitary Paper Product Manufacturing
Manufacturing
Link
United States of America
MALVERN

About OCGN

ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.